Home
Storia in 1 fonti
The legacy approach to real-world data is costing you
The life sciences industry currently has access to more real-world data (RWD) than at any point in its history. | Life sciences teams are sourcing and managing data with a hidden cost: missed patients, missed project/launch windows and incomplete decisions.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
The legacy approach to real-world data is costing you
The life sciences industry currently has access to more real-world data (RWD) than at any point in its history. | Life sciences teams are sourcing and managing data with a hidden…
- ·
Beyond China and Japan: How biopharma is expanding rare disease access across Asia-Pacific
Of the 400 million patients worldwide diagnosed with rare diseases, about 250 million of them live in North and Southeast Asia1. | While the demand in Asia-Pacific clearly exists,…
- ·
How lab data powers precision commercialization to drive therapy adoption
Drug commercialization depends on reaching the right physicians at the right moment. | Drug commercialization depends on reaching the right physicians at the right moment.